Form 4: Alzamend Neuro Director Milton C. Ault III Reports Acquisition of Common Stock

Milton C. Ault III, a director and 10% owner of Alzamend Neuro, Inc., reported the acquisition of 2,000 shares of common stock at a price of $1.0635 per share.

Summary

• On January 5, 2024, Milton C. Ault III, a director and 10% owner of Alzamend Neuro, Inc., acquired 2,000 shares of common stock at $1.0635 per share.
• Following this transaction, Mr. Ault directly owns 166,865 shares and indirectly owns 770,365 shares through Ault Lending, LLC, 996,197 shares through Ault Life Sciences, Inc., and 5,498 shares through Ault Life Sciences Fund, LLC.
• Ault Lending, LLC is a wholly-owned subsidiary of Ault Alliance, Inc., where Mr. Ault serves as Executive Chairman and has voting and investment power over the securities held by Ault Lending.
• Mr. Ault has sole voting and investment power over the securities held by Ault Life Sciences, Inc. and Ault Life Sciences Fund, LLC.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a transaction. The acquisition of shares by a director could be seen as a positive signal, but without further context, it's difficult to assess the overall impact.

Positives

• The acquisition of shares by a director and significant shareholder may signal confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders. These filings are closely monitored by investors to gauge insider sentiment and potential future stock performance.

Stakeholder Impact

• The reported transaction provides shareholders with insight into the actions of a key insider, which can influence investor confidence.

Key Dates

Keywords

Alzamend Neuro, ALZN, Milton C. Ault III, Form 4, Beneficial Ownership, Stock Acquisition, Director, 10% Owner, Ault Lending, Ault Life Sciences